CBER To Train Foreign Regulators On Biologics Review
This article was originally published in The Pink Sheet Daily
Executive Summary
October seminar is planned in response to international requests; CDER will hold companion forum.
You may also be interested in...
Pending Approvals Hold Major Implications For Myozyme Growth
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.
Waxman And Hatch Foresee Follow-on Biologics Bill Regaining Momentum – In 2009
Closing window for congressional action, lack of House consensus and Sen. Kennedy’s absence among reasons the issue will be held until next year, they suggest.
Positive Benefit-Risk Is EMEA’s Post-Market Drug Safety Watchword
Speaking at the DIA annual meeting, EMEA officer says agency is implementing a more proactive method for postmarketing risk management.